Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — Investor Presentation (May 2019)
22 slides from Armata Pharmaceuticals's investor presentation, May 14, 2019
Slide 1: Armata Pharmaceuticals Investor Presentation, May 14, 2019
Todd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer May 14, 2019 NYSE American: ARMP
Slide 2: Forward-looking statements
2 I This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All
Slide 3: Investment Highlights: A World-Leader in Phage Therapeutics
3 I • Natural phage discovery and synthetic biology yield robust pipeline – Phase 1/2 ready S. aureus natural phage product candidate – P. aeruginosa phage product candidates • Pneumonia and cystic fibrosis natural phage product candidates identified • Synthetic phage with improved pharmacology engi
Slide 4: Armata Stands on Long History of Phage Development
4 I Armata Stands on Long History of Phage Development M&A Yields Leading Phage Company Biocontrol Ltd. Pre - IND S. aureus and P. aeruginosa phage SGI Asset Acquisition Synthetic phage platform ▪ Pseudomonas program ▪ Pharma partnered program GMP Facility 25 MDR Cases Under EIND Targeted Antimicrob
Slide 5: Leadership and Board of Directors
5 I Leadership and Board of Directors Diverse Public Company Drug Development Expertise Management Todd R. Patrick CEO Steve Martin CFO Brian Varnum President and CDO Duane Morris VP, Operations Board of Directors Richard Bastiani Chair Joseph M. Patti Richard Bear Michael S. Perry Jeremy Curnock Co
Slide 6: Unmet Need in Antibiotic Resistant Infections
6 I Unmet Need in Antibiotic Resistant Infections Phages May Provide a Solution to an Urgent Public Health Threat
Slide 7: Bacteriophages (Phages)
7 I • The most ubiquitous organisms on Earth • Natural predators of bacteria • Highly targeted, exists in harmony with prey – Specific phage engineering can enhance their killing ability, lowers resistance • Low cost of goods – Low cost to manufacture a dose – Replication at site of infection; requi
Slide 8: Mechanism of Action Distinct From Antibiotics
8 I Mechanism of Action Distinct From Antibiotics Phage Infection Lyses Target Cell, Yields Progeny Phage binds target bacteria Injection of phage DNA, replication, and production of phage proteins Phage assembly Bacterial cell bursts, releasing progeny phages that then bind neighboring target bacte
Slide 9: Pipeline: Multiple Opportunities for Value Creation
9 I Pipeline Multiple Opportunities for Value Creation Pathogen Indications Discovery Preclinical Phase 1 Phase 2 Staphylococcus aureus Bacteremia Pseudomonas aeruginosa Respiratory Undisclosed Undisclosed Partnered AP - SA01 Phage libraries to address market expansion and new indications
Slide 10: AP-SA01 Phage Product Candidate Targeting S. aureus
10 I AP - SA01 Phage Product Candidate Targeting S. aureus Drug product 3 natural phages Covers >95% of S. aureus clinical isolates, including multidrug - resistant isolates Human dosing (US FDA: EIND; Aust TGA: SAS) 15 patients with serious infections not responding to antibiotics • Bacteremia, end
Slide 11: AP-SA01 Advanced Through Pre-IND Meeting
11 I AP - SA01 Advanced Through Pre - IND Meeting • Highlighted prior human exposure under expanded access programs in U.S. and Australia • General agreement on proposed trial designs (Phase 1/2) • Nonclinical data not required; in line with FDA’s flexible approach to non - traditional antimicrobial
Slide 12: Bacteremia Lead Indication for AP-SA01
12 I Bacteremia Lead Indication for AP - SA01 • 1.5 million Americans develop bacteremia each year resulting in ~250,000 deaths 1 • 1 in 3 patients who die in hospital have bacteremia 1 • The most costly condition treated at U.S. hospitals; ~$24 billion annually 2 • S. aureus is the second most comm
Slide 13: AP-SA01 Path Forward
13 I • Phase 1b/2a study in S. aureus bacteremia – Dose escalation – PK/PD with efficacy endpoints – Safety and tolerability – Cohort expansion • Recruit additional patients to optimized dose and schedule determined in Phase 1b • Pursuit of additional indications – Seek synergies between Staphylococ
Slide 14: Synthetic Pseudomonas Phage Product Candidate
14 I Synthetic Pseudomonas Phage Product Candidate Improving Natural Phage Through Engineering Natural phage provide basis for engineering 4 phage drug candidates identified 2 phage engineered Improved product characteristics through engineering Expanded host range Improved bactericidal and biofilm
Slide 15: Pseudomonas Phage Production and Formulation
15 I Pseudomonas Phage Production and Formulation Liquid formulation for first - in - human trial • Suitable for IV and inhalation Successful manufacturing of first 2 Pseudomonas phage • GMP lots at intended Phase 1 scale Test Specification Synthetic Phage 1 Phage 2 Potency (PFU/mL) ≥1 x 10 9 1.76 x
Slide 16: Synthetic Pseudomonas Phage Path Forward
16 I Planned Phase 1b First - In - Human study: • Demonstrate safety of synthetic phage and identify dose and ROA for efficacy studies • Patients with confirmed drug - resistant P. aeruginosa lung infections • Test phage - based Dx as tool to identify patients with susceptible isolates Next steps: •
Slide 17: Indication-Centric Approach
17 I Indication - Centric Approach Pseud and Staph Cover Significant Proportion of Respiratory Infections Pseudomonas aeruginosa • Covers ~20% of hospitalized pneumonia • Present in ~70% of chronic CF patients over age 25 – Major predictor of morbidity, mortality Staphylococcus aureus • Covers ~30 -
Slide 18: Class-Leading cGMP Manufacturing
18 I Class - Leading cGMP Manufacturing In - House CMC Capabilities Facilitate Rapid Advancement of Phage Into Clinic • Process development: fermentation, clarification, purification • Bioanalytical method development • Quality management systems in place (QC and QA) • cGMP production, aseptic fill
Slide 19: Strong Global IP Position Through Pending and Issued Patents
19 I Strong Global IP Position Through Pending and Issued Patents 12 Patent Families, Long - Life Patents, Patents Granted in all Major Jurisdictions Expiries through 2038 Armata’s patents and applications cover: Lead therapeutic phage cocktails (Staphylococcus and Pseudomonas) and uses thereof Comp
Slide 20: Anticipated Milestones 2019/2020
20 I AP - SA01 • Initiate Phase 1/2 clinical study in bacteremia Pseudomonas synthetic phage candidate • Conduct Pre - IND meeting and file IND • Initiate first - in - human clinical study Corporate Partnership • Achieve 1 st milestone in Merck - partnered synthetic phage program Anticipated Milesto
Slide 21: Investment Highlights
21 I Investment Highlights A World - Leader in Phage Therapeutics Lead candidate, AP - SA01, to enter clinical development in mid - 2019 Natural phage discovery and synthetic biology yield robust pipeline Merck partnership to develop proprietary synthetic phage to target an undisclosed infectious di
Slide 22: Armata Pharmaceuticals
'~ ARMATA PHARMACEUTICALS PURPOSEFUL @ PRECISE ¢ POWERFUL
Armata Pharmaceuticals — Investor Presentation (May 2019) on 6ix